接受奥氮平治疗患者的内脏脂肪和皮下脂肪：病例系列
Visceral and subcutaneous fat in patients treated with olanzapine: a case series.
作者信息
Gilles Maria, Hentschel Frank, Paslakis Georgios, Glahn Valerie, Lederbogen Florian, Deuschle Michael
机构信息
Department of Psychiatry and Psychotherapy, and †Neuroradiology, Central Institute of Mental Health, Mannheim, Germany.
出版信息
Clin Neuropharmacol. 2010 Sep-Oct;33(5):248-9. doi: 10.1097/WNF.0b013e3181f0ec33.
OBJECTIVES
We hypothesized that olanzapine may contribute to visceral adiposity, a core symptom of metabolic syndrome.
METHODS
Using computed tomography, we examined the effect of olanzapine on visceral and subcutaneous fat distribution, body mass index, fasting glucose, and lipids in an unselected population of 14 schizophrenic patients.
RESULTS
We found a 6-week olanzapine treatment to be related to increased body mass index and proportion of total fat at the level of the fourth vertebral body.
CONCLUSIONS
On the basis of these findings, we conclude that weight gain after a 6-week olanzapine treatment is partly attributable to increased visceral fat and may thus contribute to metabolic syndrome.
目的
我们推测奥氮平可能导致内脏肥胖，这是代谢综合征的一个核心症状。
方法
我们使用计算机断层扫描，在14名未经过挑选的精神分裂症患者群体中，研究了奥氮平对内脏和皮下脂肪分布、体重指数、空腹血糖及血脂的影响。
结果
我们发现，接受为期6周的奥氮平治疗与体重指数增加以及第四椎体水平的总脂肪比例增加有关。
结论
基于这些发现，我们得出结论，为期6周的奥氮平治疗后体重增加部分归因于内脏脂肪增加，因此可能导致代谢综合征。
Zotero 插件